BRAF/MEKi also promote the recruitment and/or expansion of cytotoxic CD8 + T-cells [19], increase T-cell killing [20] and enhance T-cell recognition of melanoma cells by promoting HLA class I [17] and antigen expression on tumour cells [17]. Here, CD8A is linked to melanoma.